Daewoong Co Ltd
KRX:003090
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15 050
27 400
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Daewoong Co Ltd
Net Income (Common)
Daewoong Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Daewoong Co Ltd
KRX:003090
|
Net Income (Common)
₩123.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
24%
|
CAGR 10-Years
17%
|
|
|
Yuhan Corp
KRX:000100
|
Net Income (Common)
₩165.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
31%
|
CAGR 10-Years
6%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Net Income (Common)
-₩32.9B
|
CAGR 3-Years
49%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Net Income (Common)
₩105B
|
CAGR 3-Years
25%
|
CAGR 5-Years
45%
|
CAGR 10-Years
17%
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Net Income (Common)
₩160.7B
|
CAGR 3-Years
28%
|
CAGR 5-Years
40%
|
CAGR 10-Years
17%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Net Income (Common)
₩5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-6%
|
|
Daewoong Co Ltd
Glance View
Daewoong Co., Ltd. engages in the management of its subsidiaries. The company is headquartered in Seongnam, Gyeonggi-Do. The firm operates its business mainly through subsidiaries including Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, Daewoong Development Co Ltd, and Hanall Biopharma Co Ltd. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd and Hanall Biopharma Co Ltd are engaged in the manufacture and sale of pharmaceuticals. Daewoong Development Co Ltd is engaged in real estate rental and supply business. In addition, IDS&Trust Co Ltd manufactures and sells communication-related devices. Daewoong Life Science Co Ltd is engaged in food processing and sales. Pampaeg Co Ltd is engaged in the packaging business of quasi-drugs. Daewoong Management Development Institute Co Ltd is engaged in management and industrial training projects.
See Also
What is Daewoong Co Ltd's Net Income (Common)?
Net Income (Common)
123.4B
KRW
Based on the financial report for Sep 30, 2024, Daewoong Co Ltd's Net Income (Common) amounts to 123.4B KRW.
What is Daewoong Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
17%
Over the last year, the Net Income (Common) growth was 0%. The average annual Net Income (Common) growth rates for Daewoong Co Ltd have been 5% over the past three years , 24% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
